Earnings Call · Q2 FY2022·2022-05-09

Q2 22EPS -15.60%·Rev n/aQ1 22EPS -33.33%·Rev n/aQ4 21EPS -2.52%·Rev n/aQ3 21EPS +7.75%·Rev n/a⚠ consensus missing

ENANTA PHARMACEUTICALS INC ENTA

Jennifer Viera — Investor Relations

Jay Luly — President and Chief Executive Officer

Paul Mellett — Chief Financial Officer

+6.5%1d on move date+6.3% vs SPY3d−4.7%5d−7.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ENTA calls or request research access.

More ENTA calls Browse calls Request research access